JFG
PTCT icon

Jefferies Financial Group’s PTC Therapeutics PTCT Stock Holding History

Jefferies Financial Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,400
Closed -$369K – 1951
2023
Q4 		$369K Sell
13,400
-16,600
-55% -$380K ﹤0.01% 1321
2023
Q3 		$672K Buy
+30,000
New +$1.12M 0.01% 955

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Financial Group's PTCT Position: Q1 2026 in Review

Jefferies Financial Group reduced its PTC Therapeutics (PTCT) stake by 18% in Q1 2026, selling an estimated $21.5M and leaving 1,354,459 shares worth $92.3M. The position accounts for 0.63% of the portfolio, ranked #18.

Jefferies Financial Group first reported a position in PTCT in Q1 2023 and has held it in 10 quarters since. The position peaked at $126M in Q4 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Jefferies Financial Group held 1,354,459 shares of PTC Therapeutics worth $92.3M as of Q1 2026.
  • Jefferies Financial Group sold 304,022 PTC Therapeutics shares in Q1 2026, an estimated $21.5M.
  • PTC Therapeutics made up 0.63% of Jefferies Financial Group's portfolio in Q1 2026, its #18 holding.
  • Jefferies Financial Group first reported a position in PTC Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • Jefferies Financial Group's PTC Therapeutics position peaked at $126M in Q4 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.